Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14973454 | 1.00 | KDM1A (0.50) | KDM1AMAPTHSD11B1HDAC4HDAC2 | |
| SCHEMBL5668812 | 0.97 | — | — | |
| SCHEMBL123151 | 0.93 | KDM1A (0.48) | KDM1AMAPTHSD11B1HDAC2NPC1 | |
| SCHEMBL1053630 | 0.93 | KDM1A (0.48) | KDM1AMAPTHSD11B1HDAC2NPC1 | |
| SCHEMBL6682662 | 0.93 | KDM1A (0.48) | KDM1AMAPTHSD11B1HDAC2NPC1 | |
| SCHEMBL5699292 | 0.93 | KDM1A (0.48) | KDM1AMAPTHSD11B1HDAC2NPC1 | |
| SCHEMBL8361882 | 0.93 | KDM1A (0.48) | KDM1AMAPTHSD11B1HDAC2NPC1 | |
| SCHEMBL235344 | 0.93 | KDM1A (0.48) | KDM1AMAPTHSD11B1HDAC2NPC1 | |
| SCHEMBL20552191 | 0.93 | KDM1A (0.48) | KDM1AMAPTHSD11B1HDAC2NPC1 | |
| SCHEMBL693557 | 0.93 | KDM1A (0.48) | KDM1AMAPTHSD11B1HDAC2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889851-B2 | Methods for the synthesis and purification of oligomers | AGILENT TECHNOLOGIES, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| EP-2599785-A1 | Novel methods for the synthesis and purification of oligomers | Agilent Technologies, Inc. (US) | 2013-06-05 | — | — | EP | disclosed |
| US-20130137861-A1 | NOVEL METHODS FOR THE SYNTHESIS AND PURIFICATION OF OLIGOMERS | AGILENT TECHNOLOGIES, INC. (US) | 2013-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137861-A1 | NOVEL METHODS FOR THE SYNTHESIS AND PURIFICATION OF OLIGOMERS | RTCB, CACYBP, PHAX | KDM1A 2358/4885MAPT 3223/4885HSD11B1 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.